Aspira Women's Health Inc
NASDAQ:AWH

Watchlist Manager
Aspira Women's Health Inc Logo
Aspira Women's Health Inc
NASDAQ:AWH
Watchlist
Price: 0.027 USD -67.07%
Market Cap: 23.5m USD

Aspira Women's Health Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aspira Women's Health Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Aspira Women's Health Inc
NASDAQ:AWH
Operating Income
-$16.3m
CAGR 3-Years
21%
CAGR 5-Years
-1%
CAGR 10-Years
2%
Becton Dickinson and Co
NYSE:BDX
Operating Income
$3.5B
CAGR 3-Years
10%
CAGR 5-Years
18%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Operating Income
$3.8B
CAGR 3-Years
24%
CAGR 5-Years
29%
CAGR 10-Years
15%
Stryker Corp
NYSE:SYK
Operating Income
$5.4B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Operating Income
$8B
CAGR 3-Years
-6%
CAGR 5-Years
13%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.8B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
15%
No Stocks Found

Aspira Women's Health Inc
Glance View

Market Cap
23.5m USD
Industry
Health Care

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 106 full-time employees. The company went IPO on 2000-09-29. Its products include OVA1 and Overa, OVA1plus, Aspira GenetiX and Aspira Synergy. OVA1 is a blood test that is intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical, and Overa is intended to maintain OVA1’s high sensitivity. OVA1plus is a reflex test performed for those OVA1 test results that are in the intermediate risk range. Aspira GenetiX is a genetic test for gynecologic cancer risk, with a focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers. Aspira Synergy is an en-suite, cloud-based technology transfer solution that provides an end-to-end solution from specimen collection to a customized white-label report for clinical laboratories to internalize testing of its products.

AWH Intrinsic Value
0.228 USD
Undervaluation 88%
Intrinsic Value
Price

See Also

What is Aspira Women's Health Inc's Operating Income?
Operating Income
-16.3m USD

Based on the financial report for Dec 31, 2024, Aspira Women's Health Inc's Operating Income amounts to -16.3m USD.

What is Aspira Women's Health Inc's Operating Income growth rate?
Operating Income CAGR 10Y
2%

Over the last year, the Operating Income growth was 14%. The average annual Operating Income growth rates for Aspira Women's Health Inc have been 21% over the past three years , -1% over the past five years , and 2% over the past ten years .

Back to Top